[Skip to Content]
[Skip to Content Landing]
Views 999
Citations 0
Research Letter
August 22, 2019

Use and Cost of a Hypoglossal Nerve Stimulator Device for Obstructive Sleep Apnea Between 2015 and 2018

Author Affiliations
  • 1Massachusetts Eye and Ear, Boston, Massachusetts
  • 2Harvard Business School, Boston, Massachusetts
  • 3The Warren Alpert Medical School of Brown University, Providence, Rhode Island
  • 4Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts
JAMA Otolaryngol Head Neck Surg. 2019;145(10):975-977. doi:10.1001/jamaoto.2019.2366

More than 17 million patients in the United States have obstructive sleep apnea,1 a condition associated with sequelae such as daytime somnolence, motor vehicle crashes, and cardiovascular disease.2 Continuous positive airway pressure devices are the first-line treatment for obstructive sleep apnea, although the effectiveness of such treatment is often limited by patient noncompliance.2 Second-line treatments (eg, oral appliances and palatal surgery) exist, but the available evidence offers limited support for such alternatives.2